Siemens Healthcare’s Versant 440 Molecular System gets FDA approval

Siemens Healthcare’s VERSANT 440 Molecular System has been approved for marketing by the US Food and Drug Administration (FDA).

It is to be utilised alongside the Versant HCV RNA 3.0 assay for management of HVC-infected patients undergoing antiviral therapy.

The branched DNA system is designed for flexible walk-away automation and "streamlines" work flow by integrating bar code data entry, automated reagent processing and signal amplification detection.

According to the company, it represents "next generation" automated viral load testing – which can furnish laboratories with the ability to produce "greater throughput" and maximise productivity.

"We are pleased to offer clinical laboratories leading-edge solutions in molecular diagnostics that support cost-effective and timely screening and treatment of infectious disease," said Jim Reid-Anderson, chief executive officer, Siemens Healthcare Diagnostics Division.

He added that the new system is an "outstanding" tool which delivers personalised treatment for each patient.

Siemens Healthcare offers a wide range of performance-driven diagnostics solutions around the globe.